Yan‐Jun Xiang

497 total citations · 1 hit paper
32 papers, 302 citations indexed

About

Yan‐Jun Xiang is a scholar working on Hepatology, Surgery and Pathology and Forensic Medicine. According to data from OpenAlex, Yan‐Jun Xiang has authored 32 papers receiving a total of 302 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hepatology, 13 papers in Surgery and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Yan‐Jun Xiang's work include Hepatocellular Carcinoma Treatment and Prognosis (26 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (13 papers) and Cancer Mechanisms and Therapy (10 papers). Yan‐Jun Xiang is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (26 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (13 papers) and Cancer Mechanisms and Therapy (10 papers). Yan‐Jun Xiang collaborates with scholars based in China, Hong Kong and United States. Yan‐Jun Xiang's co-authors include Yuqiang Cheng, Kang Wang, Hongming Yu, Shuqun Cheng, Wei‐Xing Guo, Shuqun Cheng, Liping Zhou, Yingyi Qin, Jie Shi and Wan Yee Lau and has published in prestigious journals such as Nature Medicine, Frontiers in Immunology and International Journal of Biological Macromolecules.

In The Last Decade

Yan‐Jun Xiang

28 papers receiving 299 citations

Hit Papers

Adjuvant sintilimab in resected high-risk hepatocellular ... 2024 2026 2025 2024 20 40 60
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
    2024 64 citations Kang Wang, Yan‐Jun Xiang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yan‐Jun Xiang China 11 232 88 78 72 69 32 302
Guosheng Yuan China 11 255 1.1× 77 0.9× 146 1.9× 62 0.9× 71 1.0× 40 344
Najib Ben Khaled Germany 9 106 0.5× 68 0.8× 71 0.9× 33 0.5× 48 0.7× 40 258
Maridi Aerts Belgium 8 143 0.6× 75 0.9× 60 0.8× 20 0.3× 88 1.3× 26 256
Guohong Han China 9 218 0.9× 42 0.5× 81 1.0× 74 1.0× 36 0.5× 17 271
Zexin Zhu China 10 136 0.6× 64 0.7× 85 1.1× 29 0.4× 67 1.0× 19 304
Alexander Vasilyev Russia 2 196 0.8× 158 1.8× 66 0.8× 61 0.8× 74 1.1× 3 284
Vincent E. Gaillard Switzerland 10 229 1.0× 170 1.9× 74 0.9× 65 0.9× 75 1.1× 21 348
Zuan Lin China 9 107 0.5× 216 2.5× 103 1.3× 35 0.5× 86 1.2× 18 325
Claus Kölblinger Austria 8 324 1.4× 133 1.5× 142 1.8× 83 1.2× 59 0.9× 10 466
Mariella Di Marco Italy 4 280 1.2× 65 0.7× 223 2.9× 35 0.5× 39 0.6× 5 379

Countries citing papers authored by Yan‐Jun Xiang

Since Specialization
Citations

This map shows the geographic impact of Yan‐Jun Xiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan‐Jun Xiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan‐Jun Xiang more than expected).

Fields of papers citing papers by Yan‐Jun Xiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yan‐Jun Xiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan‐Jun Xiang. The network helps show where Yan‐Jun Xiang may publish in the future.

Co-authorship network of co-authors of Yan‐Jun Xiang

This figure shows the co-authorship network connecting the top 25 collaborators of Yan‐Jun Xiang. A scholar is included among the top collaborators of Yan‐Jun Xiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yan‐Jun Xiang. Yan‐Jun Xiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Kang, Hongming Yu, Yuqiang Cheng, et al.. (2025). Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial. Signal Transduction and Targeted Therapy. 10(1). 328–328.
2.
Zhang, Fuxiang, Yan‐Jun Xiang, Xueying Ding, et al.. (2025). Development of a new nomogram for predicting recurrence in HCC with MVI following curative hepatectomy. International Journal of Surgery. 112(2). 3854–3864.
3.
4.
5.
Wang, Yujie, Y P Feng, Hongyu Tu, et al.. (2024). Photothermal-manipulatable shape memory polyacrylamide/gelatin Janus hydrogel with drug carrier array for invasive wound closure and responsive drug release. International Journal of Biological Macromolecules. 293. 139255–139255. 4 indexed citations
6.
7.
8.
Wang, Kang, et al.. (2023). Preoperative and Prognostic Prediction of Microvascular Invasion in Hepatocellular Carcinoma: A Review Based on Artificial Intelligence. Technology in Cancer Research & Treatment. 22. 2223954614–2223954614. 6 indexed citations
9.
Wang, Weijun, Kang Wang, Hongming Yu, et al.. (2023). Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study. Cancer Medicine. 12(10). 11513–11524. 20 indexed citations
10.
Zhang, Yuqing, Chong‐De Lu, Liu Xu, et al.. (2023). Transarterial chemoembolization plus immune checkpoint inhibitor as postoperative adjuvant therapy for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter cohort study. European Journal of Surgical Oncology. 49(7). 1226–1233. 5 indexed citations
11.
Wang, Kang, Yan‐Jun Xiang, Hongming Yu, et al.. (2023). Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation. BMC Cancer. 23(1). 1017–1017. 3 indexed citations
12.
13.
14.
Chai, Zong‐Tao, Xiuping Zhang, Zhenhua Chen, et al.. (2023). A reasonable identification of the early recurrence time based on microvascular invasion for hepatocellular carcinoma after R0 resection: A multicenter retrospective study. Cancer Medicine. 12(9). 10294–10302. 6 indexed citations
15.
Wang, Kang, Yan‐Jun Xiang, Jiangpeng Yan, et al.. (2022). A deep learning model with incorporation of microvascular invasion area as a factor in predicting prognosis of hepatocellular carcinoma after R0 hepatectomy. Hepatology International. 16(5). 1188–1198. 10 indexed citations
16.
Xiang, Yan‐Jun, Kang Wang, Shuang Feng, et al.. (2022). Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory. Frontiers in Oncology. 12. 839605–839605. 17 indexed citations
17.
Wang, Kang, Hongming Yu, Yan‐Jun Xiang, et al.. (2022). Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol. BMJ Open. 12(12). e064688–e064688. 2 indexed citations
18.
19.
Xiang, Yan‐Jun, Juxian Sun, Jiayi Wu, et al.. (2022). Recurrence hazard rate in patients with hepatocellular carcinoma and bile duct tumor thrombus: a multicenter observational study. HPB. 24(10). 1703–1710. 2 indexed citations
20.
Wang, Kang, Yan‐Jun Xiang, Hongming Yu, et al.. (2021). A novel classification in predicting prognosis and guiding postoperative management after R0 liver resection for patients with hepatocellular carcinoma and microvascular invasion. European Journal of Surgical Oncology. 48(6). 1348–1355. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guosheng Yuan Breakdown of academic impact, for papers by Najib Ben Khaled Breakdown of academic impact, for papers by Maridi Aerts Breakdown of academic impact, for papers by Guohong Han Breakdown of academic impact, for papers by Zexin Zhu Breakdown of academic impact, for papers by Alexander Vasilyev Breakdown of academic impact, for papers by Vincent E. Gaillard Breakdown of academic impact, for papers by Zuan Lin Breakdown of academic impact, for papers by Claus Kölblinger Breakdown of academic impact, for papers by Mariella Di Marco
Rankless by CCL
2026